Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0202 • ACR Convergence 2024
Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei¹, Hui Zhao¹, Suja Rajan³, Heather Lin¹ and Sharon Giordano¹, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson, Houston, TX, ³The University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: There is concern about the use of tumor necrosis factor inhibitors (TNFi) in patients with early cancer given their immunosuppressant effects. Few studies have…
Abstract Number: 0310 • ACR Convergence 2024
I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study
Amine Mouamnia, Armentieres Hospital Center, Armentieres, France
Background/Purpose: Inflammatory and auto-immune disease are associated to comordities. Indeed, patients suffering from arthritis rheumatoid disease (ARD) such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR)…
Abstract Number: 0449 • ACR Convergence 2024
Evaluating Premenstrual Dysphoric Disorder in Women with Rheumatoid Arthritis and Healthy Female Subjects
Ana Cecilia Bardan-Inchaustegui¹, Iris Jazmín Colunga Pedraza², Rosa Icela Arvizu-Rivera², Gisela Garcia-Arellano³, Griselda Serna-Peña⁴, Maria F. Elizondo-Benitez⁵, Aleydis Gonzalez Melendez², Fernanda Massiel Garcia⁶ and Dionicio Galarza-Delgado⁷, ¹Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Hospital Universitario \"Dr. José Eleuterio González\", Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", UANL, Monterrey, Mexico, ⁵Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁶Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome, is classified as a psychiatric disorder characterized by moderate to severe physical, affective, or…
Abstract Number: 0471 • ACR Convergence 2024
Understanding the Role of the Complement System in Insulin Resistance and Metabolic Syndrome in Patients with Rheumatoid Arthritis
Jose Viotti-Serra¹, Maria Garcia-Gonzalez², Fuensanta Gomez-Bernal¹, Juan Carlos Quevedo-Abeledo³, Miguel Angel Gonzalez-Gay⁴ and ivan Ferraz-Amaro⁵, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ²Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Background/Purpose: The complement (C) system has been associated with the etiopathogenesis of rheumatoid arthritis (RA). Insulin resistance (IR) and metabolic syndrome are prevalent among RA…
Abstract Number: 0488 • ACR Convergence 2024
Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis
Pablo Martínez Calabuig¹, Elena Grau García², Samuel Leal Rodriguez², Ernesto Tovar Sugrañes³, José Ivorra-Cortés⁴, Carmen Riesco Barcena³, Anderson Huaylla Quispe³, Laura Mas Sánchez⁵, Pablo Muñoz Martínez⁶, Daniel Ramos Castro³, Alba Torrat noves⁷, Iago Alcantara Alvarez⁸, Belén Villanueva Mañés⁸, Miguel Simeo Vinaixa⁸, Andrés Pérez Hurtado³ and Jose A Román-Ivorra⁹, ¹HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ²HUP La Fe, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁵Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁶Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to…
Abstract Number: 0505 • ACR Convergence 2024
UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi
George Karpouzas¹, Lixia Zhang², Mark Zielinski², Brian Cheng² and Sherry Guardiano³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corporation, Keene, NH
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
Abstract Number: 0523 • ACR Convergence 2024
Distinct Peripheral Blood Immune Cell Sub-population Signatures at Baseline of Tofacitinib or Adalimumab Initiation Are Associated to Clinical Responses at 6 Months
Panagiota Goutakoli¹, Eirini Sevdali¹, Elpida Neofotistou-Themeli¹, Argyro Repa², Nestor Avgoustidis³, Sofia Pitsigavdaki⁴, Eleni Kalogiannaki², George Bertsias⁵, Nikolaos Paschalidis⁶, Panayotis Verginis⁷ and Prodromos Sidiropoulos⁸, ¹University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation, Heraklion, Greece, ²University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ³University Hospital, Rheumatology and Clinical Immunology,, Heraklion, Greece, ⁴Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece, Heraklion, Greece, ⁵Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ⁶Biomedical Research Foundation, Academy of Athens, Athens, Greece, ⁷Medical School, University of Crete, Heraklion, Crete, Greece, ⁸University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece
Background/Purpose: Biomarkers to predict response to tofacitinib or adalimumab are not clinically available. Herein we aimed to characterize peripheral blood immune cell subsets with a…
Abstract Number: 0771 • ACR Convergence 2024
Arid5b Controls Pathologic Inflammatory versus Invasive Fibroblast Behavior
Angela Zou¹, Suppawat Kongthong², Cassandra Murphy², Gerald Watts³, Alisa Mueller⁴ and Michael Brenner⁵, ¹Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Brookline, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: Synovial fibroblasts assume both inflammatory and tissue invasive roles in rheumatoid arthritis (RA). Recent studies have shown that these inflammatory and invasive functions are…
Abstract Number: 0872 • ACR Convergence 2024
Investigating the Natural Improvement of Rheumatoid Arthritis During Pregnancy
Matthew Wright¹, Dana Goin², Mette Kiel Smed³, Nicholas Jewell⁴, J Lee Nelson⁵, Merete Hetland⁶ and Damini Jawaheer⁷, ¹Children's Hospital Oakland Research Institute/Northwestern University, Chicago, ²UCSF, San Francisco, CA, ³Juliane Marie Centret, Copenhagen, Denmark, ⁴UC Berkeley, Berkeley, CA, ⁵University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, ⁶Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁷Children's Hospital Oakland Research Institute/Northwestern University, Chicago, IL
Background/Purpose: Pregnancy can induce a natural improvement of rheumatoid arthritis (RA) in 50-75% of women with the disease, while others may worsen or remain unchanged.…
Abstract Number: 0938 • ACR Convergence 2024
Group 2 Innate Lymphoid Cells Promote T Cell Activation and Development of Autoimmune Arthritis
Agnieszka Lastowska¹, Anders Nguyen², Miriam Bollmann² and Mattias Svensson³, ¹University of Gothenburg, Goteborg, Sweden, ²University of Gothenburg, Göteborg, Sweden, ³University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Innate Lymphoid Cells (ILCs) are the innate counterparts to T cells and can be divided into three functionally distinct subpopulations: Group 1 (ILC1), Group…
Abstract Number: 0990 • ACR Convergence 2024
Predictors of Adverse Events and Complications in Cirrhotic Patients with Rheumatoid Arthritis: A Nationwide Analysis
Nidaa Rasheed¹, Humzah Iqbal² and Candice Reyes³, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³VACCHCS, Fresno, CA
Background/Purpose: Cirrhosis is associated with a host of complications such as coagulopathy, renal impairment, esophageal varices, peritonitis, and increased mortality. Rheumatoid arthritis (RA) is a…
Abstract Number: 1042 • ACR Convergence 2024
Identifying Patient Priorities for Patient-Reported Outcome Measures in Rheumatoid Arthritis: A Modified Delphi Consensus Study
Racheal Githumbi¹, Steven Katz², Ania Kania-Richmond¹, Kim Giroux³, Yvonne Wallace³, Cheryl Barnabe¹, Glen Hazlewood¹, C. Allyson Jones², Amanda Steiman⁴, Anshula Ambasta¹, Diane Lacaille⁵, Elaine Yacyshyn², Jessica Widdifield⁶, Natasha Gakhal⁷, Tyler Williamson¹ and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Patient Partner, Calgary, AB, Canada, ⁴Sinai Health System, Toronto, ON, Canada, ⁵Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁶Sunnybrook Research Institute / ICES / UofT Institute of Health Policy, Management & Evaluation, Toronto, ON, Canada, ⁷Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Patient-reported outcome measures (PROMs) are essential tools for prioritizing patient-centric care and enhancing health system-performance measurement in rheumatology. Effective use of PROMs collected in…
Abstract Number: 1249 • ACR Convergence 2024
Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry
Shilpa Venkatachalam¹, Kelly Gavigan², Erik Stone³, Angela Degrassi², Laura Stradford⁴, David Curtis², Esteban Rivera⁵ and Jeffrey Curtis⁶, ¹Global Healthy Living Foundation, New York, NY, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, Upper Nyack, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…
Abstract Number: 1338 • ACR Convergence 2024
Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Mark Tatangelo³ and Claire Bombardier³, and OBRI investigators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) have approximately a twofold increased risk of developing herpes zoster (HZ) compared to the general population. This elevated risk is attributed…
Abstract Number: 1354 • ACR Convergence 2024
The Association of Genetic Variation in PTPN22 and Rheumatoid Arthritis Disease Activity
Thomas Riley¹, Austin Wheeler², Bryant England², grant Cannon³, Sauer brian⁴, Gary Kunkel⁵, Katherine Wysham⁶, Beth Wallace⁷, Rachel Elam⁸, Paul Monach⁹, Andreas Reimold¹⁰, Gail Kerr¹¹, Isaac Smith¹², John Richards¹³, Iris Lee¹⁴, Rui Xiao¹⁵, Scott Damrauer¹⁵, Michael George¹⁵, Ted Mikuls² and Joshua Baker¹⁵, ¹Hopsital of the University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁷Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁸Augusta University, Evans, GA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰Dallas VA Medical Center, Dallas, TX, ¹¹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹²Duke University Hospital, Durham, NC, ¹³Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁴Washington University in St Louis, Saint Louis, MO, ¹⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: PTPN22 R620W is a common genetic variation that is a known risk factor for the development of autoimmune disease, including rheumatoid arthritis (RA). This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].